KYL

• CAT Number: P000295
• CAS Number: 676657-00-4
• Molecular Formula: C74H108N14O17
• Molecular Weight: 1465.76
• Purity: ≥95%
• Target: Ephrin Receptor
• Solubility: Soluble to 2 mg/ml in water
• Storage: Store at -20C
• IUPAC Name: (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoic acid
• InChI: InChI=1S/C74H108N14O17/c1-40(2)31-52(64(94)84-59(39-90)68(98)85-58(38-89)67(97)83-57(74(104)105)33-42(5)6)80-71(101)62(43(7)8)86-70(100)61-19-14-30-88(61)73(103)56(36-46-37-77-51-17-10-9-15-49(46)51)82-66(96)54(35-45-22-26-48(92)27-23-45)79-69(99)60-18-13-29-87(60)72(102)55(32-41(3)4)81-65(95)53(34-44-20-24-47(91)25-21-44)78-63(93)50(76)16-11-12-28-75/h9-10,15,17,20-27,37,40-43,50,52-62,77,89-92H,11-14,16,18-19,28-36,38-39,75-76H2,1-8H3,(H,78,93)(H,79,99)(H,80,101)(H,81,95)(H,82,96)(H,83,97)(H,84,94)(H,85,98)(H,86,100)(H,104,105)/t50-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-/m0/s1
• InChIKey: FZNPYIAZMDBRLC-RKNDTPCJSA-N
• SMILES: CC(C)CC(C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(C(C)C)NC(=O)C1CCCN1C(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C5CCCN5C(=O)C(CC(C)C)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CCCCN)N

KYL(CAT: P000295) is a potent inhibitor of the EphA4 receptor tyrosine kinase, exhibiting a dissociation constant of 0.8 μM and effectively inhibiting EphA4-EphrinA5 interactions. This compound has demonstrated significant neuroprotective properties by preventing amyloid-beta oligomer induced synaptic damage and dendritic spine loss. Additionally, KYL prevents the blockade of long-term potentiation (LTP) in hippocampal CA3-CA1 transmissions, a critical process in synaptic plasticity and memory. Its extended half-life in cell culture media (8 hours in PC3 media and 12 hours in C2C12 media) further enhances its utility for in vitro studies. KYL is a valuable tool for exploring EphA4 signaling pathways and potential therapeutic strategies for neurodegenerative disorders.